29,486 Shares in CareDx, Inc (NASDAQ:CDNA) Bought by Mackenzie Financial Corp

Mackenzie Financial Corp bought a new stake in CareDx, Inc (NASDAQ:CDNA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 29,486 shares of the company's stock, valued at approximately $631,000. Mackenzie Financial Corp owned approximately 0.05% of CareDx at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Divisadero Street Capital Management LP bought a new position in CareDx in the 4th quarter valued at approximately $15,239,000. Jacobs Levy Equity Management Inc. lifted its stake in CareDx by 52.6% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,243,580 shares of the company's stock valued at $26,625,000 after purchasing an additional 428,864 shares during the last quarter. Bamco Inc. NY lifted its stake in CareDx by 17.6% in the 4th quarter. Bamco Inc. NY now owns 2,207,299 shares of the company's stock valued at $47,258,000 after purchasing an additional 330,627 shares during the last quarter. Vanguard Group Inc. lifted its stake in CareDx by 7.1% in the 4th quarter. Vanguard Group Inc. now owns 4,859,732 shares of the company's stock valued at $104,047,000 after purchasing an additional 323,554 shares during the last quarter. Finally, Intrinsic Edge Capital Management LLC bought a new position in CareDx in the 4th quarter valued at approximately $5,460,000.

Analysts Set New Price Targets

CDNA has been the subject of several research reports. HC Wainwright reissued a "neutral" rating and issued a $25.00 price objective on shares of CareDx in a research note on Monday, May 5th. Stephens reissued an "overweight" rating and issued a $40.00 price objective on shares of CareDx in a research note on Monday, May 5th. The Goldman Sachs Group dropped their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Finally, Wall Street Zen downgraded shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $30.33.

Insider Transactions at CareDx

In other news, Director William A. Hagstrom sold 30,000 shares of the stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $17.45, for a total transaction of $523,500.00. Following the completion of the sale, the director now directly owns 53,979 shares in the company, valued at $941,933.55. This represents a 35.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Peter Maag sold 13,281 shares of the stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63. Following the sale, the director now owns 316,743 shares of the company's stock, valued at approximately $5,457,481.89. This trade represents a 4.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 89,382 shares of company stock worth $1,458,009 over the last three months. 4.90% of the stock is owned by company insiders.

CareDx Trading Up 4.1%

CDNA traded up $0.76 during trading on Friday, reaching $19.52. 904,107 shares of the company's stock were exchanged, compared to its average volume of 907,882. CareDx, Inc has a one year low of $13.18 and a one year high of $34.84. The stock has a market capitalization of $1.09 billion, a PE ratio of -7.23 and a beta of 2.27. The firm has a fifty day moving average price of $17.32 and a two-hundred day moving average price of $20.41.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. During the same period in the previous year, the firm posted ($0.03) EPS. The company's revenue for the quarter was up 17.6% compared to the same quarter last year. Sell-side analysts expect that CareDx, Inc will post -0.9 earnings per share for the current year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.